Why is the FDA cracking down on compounded GLP-1 drugs? What its letters and statements cite

Why is the FDA cracking down on compounded GLP-1 drugs?

FDA’s dated records point to three things: the tirzepatide and semaglutide shortages that allowed wide compounding were declared resolved (December 19, 2024 and February 21, 2025), FDA found telehealth marketing that implied compounded products were the same as FDA-approved drugs (March 3, 2026), and it counted 990 adverse event reports tied to compounded semaglutide as of May 31, 2026. Of the 155 GLP-1 warning letters in this index, 141 cite false or misleading claims or unapproved or misbranded drugs, and 14 cite compounding or manufacturing (CGMP) problems.

The reasons are FDA’s, quoted from its dated statements and letter subject lines. This site does not add its own.

GLP-1 warning letters by year and subject group

Compounding / adulterated drugs00448
False or misleading claims / misbranded0005656
Manufacturing practice (CGMP)01236
Unapproved new drugs / misbranded272516
Unapproved or misbranded drugs sold online0260769

Subject groups restate FDA’s subject line on each letter; the exact subject is on the letters page.

FDA’s statements, by date

FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.

Common questions

Is the FDA banning compounded semaglutide and tirzepatide?

No FDA statement in this index announces a ban. FDA has set dated conditions: the shortages are resolved, outsourcing facilities may compound from bulk semaglutide or tirzepatide only if it is on the 503B bulks list or the shortage list (neither applied as of April 1, 2026), and on April 30, 2026 FDA proposed not adding them to the bulks list.

When did FDA start sending GLP-1 warning letters to telehealth companies?

The earliest letter labeled “(Telehealth)” in this index is dated Sep 9, 2025. FDA’s March 3, 2026 release called the February 2026 letters the second group since it began acting on misleading drug advertising in September 2025.

Does FDA approve compounded GLP-1 drugs?

No. FDA states that compounded drugs are not FDA-approved, which means it does not review their safety, effectiveness or quality before they are marketed (FDA news release, March 3, 2026).

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.